Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation
Pilot Study of Telmisartan (Micardis) For the Prevention of Acute Graft vs. Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation
Sponsor: Hackensack Meridian Health
Terminated
Lack of Accrual
Listed as NCT02338232, this NA trial focuses on GVHD and remains terminated or withdrawn. Sponsored by Hackensack Meridian Health, it has been updated 14 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jun 2024 — Jul 2024 [monthly]
Terminated NA
-
Mar 2023 — Jun 2024 [monthly]
Terminated NA
Status: Active Not Recruiting → Terminated
-
Sep 2022 — Mar 2023 [monthly]
Active Not Recruiting NA
▶ Show 9 earlier versions
-
Sep 2021 — Sep 2022 [monthly]
Active Not Recruiting NA
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting NA
-
Sep 2020 — Jan 2021 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Sep 2019 — Sep 2020 [monthly]
Recruiting NA
-
Sep 2018 — Sep 2019 [monthly]
Recruiting NA
-
Jun 2018 — Sep 2018 [monthly]
Recruiting NA
-
Aug 2017 — Jun 2018 [monthly]
Recruiting NA
-
Feb 2017 — Aug 2017 [monthly]
Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Jul 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hackensack Meridian Health
For direct contact, visit the study record on ClinicalTrials.gov .